Plasma biomarkers and cystic brosis fibrosis lung disease

Clinical and Investigative Medicine

Volumn 35, Issue 4, 2012, Pages

  Cantin, André M ^a   Bilodeau, Ginette ^a   Larivée, Pierre ^a   Richter, Martin V ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; CYTOKINE; LEUKOCYTE ELASTASE; N ACETYLNEURAMINIC ACID;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PATHOPHYSIOLOGY;

ADULT; ALPHA 1-ANTITRYPSIN; BIOLOGICAL MARKERS; CYSTIC FIBROSIS; CYTOKINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOCYTE ELASTASE; MALE; N-ACETYLNEURAMINIC ACID;

EID: 84867370892     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009 May 30;373(9678):1891-904.
2. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996 Nov;154(5):1229-56.
3. Rosenstein BJ, Cutting GR. e diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr1998 Apr; 132(4): 589-95.
4. Pilewski JM, Frizzell RA. Role of CFTR in airway disease. Physiol Rev1999; 79(1 Suppl): S215-55.
5. Hug MJ, Tamada T, Bridges RJ. CFTR and bicarbonate secretion to epithelial cells. News Physiol Sci 2003 Feb;18:38-42.
6. Ballard ST, Trout L, Bebok Z, Sorscher EJ, Crews A. CFTR involvement in chloride, bicarbonate, and liquid secretion by airway submucosal glands. Am J Physiol1999;277(4 Pt 1): L694-9.
7. Ratjen F. Update in cystic fibrosis 2008. Am J Respir Crit Care Med 2009 Mar 15;179(6): 445-8.
8. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov2009 Feb;8(2):153-71.
9. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis [see comments]. Am J Respir Crit Care Med1995;151(4):1075-82.
10. Regelmann WE, Siefierman CM, Herron JM, Elliott GR, Clawson CC, Gray BH. Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis. Pediatr Pulmonol1995;19(1):1-9.
11. Schuster A, Haarmann A, Wahn V. Cytokines in neutrophildominated airway inflammation in patients with cystic fibrosis. Eur Arch Otorhinolaryngol Suppl1995;1(60):S59-60.
12. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation [published erratum appears in Am J Respir Crit Care Med 1995 Jan;151(1):260]. Am J Respir Crit Care Med1994;150(2):448-54.
13. Birrer P, McElvaney NG, Rudeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med1994;150(1):207-13.
14. Meyer KC, Zimmerman J. Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis [see comments]. J Lab Clin Med1993;121(5):654-61.
15. Levy H, Kalish LA, Huntington I, Weller N, Gerard C, Silverman EK, et al. Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatr Pulmonol2007 Mar;42(3):256-62.
16. Eickmeier O, Huebner M, Herrmann E, Zissler U, Rosewich M, Baer PC, et al. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine2010 May;50(2):152-7.
17. Gopaul KP, Crook MA. Sialic acid: a novel marker of cardiovascular disease? Clin Biochem2006 Jul;39(7):667-81.
18. Cantin AM, Fournier A, Leduc R. Human leukocyte elastase and cystic fibrosis. In: Lendeckel U, Hooper NM, editors. Proteases in tissue remodelling of lung and heart. New York: Kluwer Academic/Plenum Publishers; 2003. p. 1-33.
19. Rayner RJ, Wiseman MS, Cordon SM, Norman D, Hiller EJ, Shale DJ. Inflammatory markers in cystic fibrosis. Respir Med1991;85(2):139-45.
20. Suter S. Elastase alpha 1-antiproteinase complexes in cystic fibrosis. J Pediatr1988;112(3):507-8.
21. Hollsing AE, Lantz B, Bergstrom K, Malmborg AS, Strandvik B. Granulocyte elastase-alpha-1-antiproteinase complex in cystic fibrosis: sensitive plasma assay for monitoring pulmonary infections. J Pediatr1987;111(2):206-11.
22. Valletta EA, Rigo A, Bonazzi L, Zanolla L, Mastella G. Modification of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis. Acta Paediatr1992;81(3):227-30.
23. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet2005 Aug 6-12;366(9484):463-71.
24. Sydow G. A simplified quick method for determination of sialic acid in serum. Biomed Biochim Acta1985;44(11-12):1721-3.
25. Shamberger RJ. Serum sialic acid in normals and in cancer patients. J Clin Chem Clin Biochem1984 Oct;22(10):647-51.
26. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J2005 Aug;26(2):319-38.
27. Ohshimo S, Bonella F, Grammann N, Starke K, Cui A, Bauer PC, et al. Serum KL-6 as a novel disease marker in adolescent and adult cystic fibrosis. Sarcoidosis Vasc Difiuse Lung Dis2009 Jul;26(1):47-53.
28. Browning LM, Jebb SA, Mishra GD, Cooke JH, O'Connell MA, Crook MA, et al. Elevated sialic acid, but not CRP, predicts features of the metabolic syndrome independently of BMI in women. Int J Obes Relat Metab Disord2004 Aug;28(8):1004-10.
29. Suter S, Schaad UB, Roux-Lombard P, Girardin E, Grau G, Dayer JM. Relation between tumor necrosis factor-alpha and granulocyte elastase- alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis [see comments]. Am Rev Respir Dis1989;140(6):1640-4.
30. Norman D, Elborn JS, Cordon SM, Rayner RJ, Wiseman MS, Hiller EJ, et al. Plasma tumour necrosis factor alpha in cystic fibrosis. orax1991;46(2):91-5.
31. Winklhofer-Roob BM, Schlegel-Haueter SE, Khoschsorur G, van't Hof MA, Suter S, Shmerling DH. Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation. Pediatr Res1996;40(1):130-4.
32. Downey DG, Martin SL, Dempster M, Moore JE, Keogan MT, Starcher B, et al. e relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol2007 Mar;42(3):216-20.
33. Martin SL, Downey D, Bilton D, Keogan MT, Edgar J, Elborn JS. Safety and effcacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol2006 Feb;41(2):177-83.
34. McGrath LT, Mallon P, Dowey L, Silke B, McClean E, McDonnell M, et al. Oxidative stress during acute respiratory exacerbations in cystic fibrosis. orax1999 Jun;54(6):518-23.
35. Reeves EP, Bergin DA, Fitzgerald S, Hayes E, Keenan J, Henry M, et al. A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis. J Cyst Fibros2012 Mar;11(2):100-7.
36. Lee WL, Downey GP. Leukocyte Elastase. Physiological functions and role in acute lung injury. Am J Respir Crit Care Med2001 Sep 1;164(5):896-904.
37. Cantin AM, Lafrenaye S, Begin RO. Antineutrophil elastase activity in cystic fibrosis serum. Pediatr Pulmonol1991;11(3):249-53.
38. Cantin A, Bilodeau G, Begin R. Granulocyte elastase-mediated proteolysis of alpha 1-antitrypsin in cystic fibrosis bronchopulmonary secretions. Pediatr Pulmonol1989;7(1):12-7.
39. Goldstein W, Doring G. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis1986;134(1):49-56.
40. Suter S, Schaad UB, Roux L, Nydegger UE, Waldvogel FA. Granulocyte neutral proteases and Pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis. J Infect Dis1984;149(4):523-31.
41. Stone PJ, Konstan MW, Berger M, Dorkin HL, Franzblau C, Snider GL. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med1995;152(1):157-62.
42. Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski JF, Jr., Dearborn DG. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis1985;132(3):529-35.
43. Suter S, Schaad UB, Tegner H, Ohlsson K, Desgrandchamps D, Waldvogel FA. Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa. J Infect Dis1986;153(5):902-9.
44. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, et al. Association between Pulmonary Function and Sputum Biomarkers in Cystic Fibrosis. Am J Respir Crit Care Med2007 Apr 15;175(8):822-8.
45. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of in-ammation in cystic fibrosis lung disease. Proc Am orac Soc2007 Aug 1;4(4):406-17.